12.26
+9.56%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Mobia Medical, Inc. Common Stock
Its shares trade under the ticker MOBI. It has been listed since 8 May 2026. In the fiscal year to 31 December 2025, it reported revenue of $32.0m and a net loss of $46.5m. At that date it held total assets of $48.1m and shareholders' equity of −$150.8m.
Mobia Medical, Inc. develops and commercializes neurostimulation medical devices, including implantable systems for stroke rehabilitation and other neurological conditions. The company provides neurostimulation systems and devices that combine vagus nerve stimulation with therapy to address chronic neurological conditions. Its main product, the Vivistim System, is an FDA-approved implantable device designed to aid in the rehabilitation of upper limb motor function in post-stroke patients. The paired VNS platform is used to help patients relearn movements and improve motor deficits, and it is being developed for additional chronic neurologic conditions such as tinnitus. The company supports healthcare professionals, patients, and caregivers with information and resources related to its offerings. The company serves healthcare professionals and organizations involved in stroke rehabilitation and chronic neurological conditions, as well as patients and caregivers within the healthcare sector. The company was founded in 2007 and is based in Austin, Texas.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Listed since
- 8 May 2026
- Website
- mobia.com ↗
- Head office
- 2802 FLINTROCK TRACE, SUITE 226, AUSTIN, TX, 78738
- Incorporated in
- DE
- Classification
- Surgical & Medical Instruments & Apparatus
- Filer status
- <br>Emerging growth company
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Mobia Medical's Vivistim System is FDA-approved for stroke rehabilitation upper limb motor function.
- The paired VNS platform addresses chronic neurological conditions like tinnitus and stroke rehabilitation.
- Mobia Medical serves healthcare professionals and patients in the US stroke rehabilitation sector.
Weaknesses
- Mobia Medical's focus on neurostimulation devices limits market diversification in the US healthcare sector.
- The company's reliance on a single FDA-approved product may pose commercial risks.
- Mobia Medical's 2007 founding year indicates limited historical market presence in neurostimulation.
Opportunities
- Expanding the Vivistim System for additional chronic neurologic conditions beyond stroke rehabilitation.
- Increasing adoption of neurostimulation devices in the US healthcare sector for neurological conditions.
- Growing demand for stroke rehabilitation solutions in the US market for post-stroke patients.
Threats
- Regulatory changes in the US FDA approval process could delay product development.
- Competition from other neurostimulation device manufacturers in the US healthcare market.
- Economic downturns affecting healthcare spending on neurostimulation therapies in the US.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.